With respect to EGFR mutations in NSCLC, what validations support routine target profiling using hybrid capture-based NGS platforms, and what target-drug alignments have improved PFS?

With respect to EGFR mutations in NSCLC, what validations support routine target profiling using hybrid capture-based NGS platforms, and what target-drug alignments have improved PFS?

With respect to EGFR mutations in NSCLC, what clinical validations exist to support routine molecular target profiling using hybrid capture-based NGS platforms, and what target-drug alignments have been shown to improve PFS outcomes?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Paul Mitchell, BHB, MBChB, FRACP, MD

Paul Mitchell, BHB, MBChB, FRACP, MD

Associate Professor
Senior Specialist
Austin Health Cancer Services
Director, North Eastern Metropolitan Integrated Cancer Services (NEMICS)
Melbourne, Australia